The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial

BACKGROUND: HER2 is one of the predominant therapeutic targets in breast cancer. The metastatic selection process may lead to discrepancies between the HER2 status of the primary tumor and circulating tumor cells (CTCs). This study analyzed the HER2 status of CTCs in patients with HER2-positive prim...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaeger, B. A. S., Neugebauer, J., Andergassen, U., Melcher, C., Schochter, F., Mouarrawy, D., Ziemendorff, G., Clemens, M., v. Abel, E., Heinrich, G., Schueller, K., Schneeweiss, A., Fasching, P., Beckmann, M. W., Scholz, Ch., Friedl, T. W. P., Friese, K., Pantel, K., Fehm, T., Janni, W., Rack, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460789/
https://www.ncbi.nlm.nih.gov/pubmed/28586395
http://dx.doi.org/10.1371/journal.pone.0173593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460789/
https://www.ncbi.nlm.nih.gov/pubmed/28586395
http://dx.doi.org/10.1371/journal.pone.0173593

Ejemplares similares